Compare Micron Technology, Inc. (MU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs BIO-TECHNE Corp — how do they compare? Micron Technology, Inc. trades at $856.5 (market cap $972.41B), while BIO-TECHNE Corp trades at $72.12 (market cap $11.24B). The key difference: Micron Technology, Inc. is far larger — about 86.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| MU | TECH | |
|---|---|---|
Market Cap | $972.41B | $11.24B |
Sector | Technology | Health |
52-Week High | $1.21K | $72.29 |
52-Week Low | $115.79 | $43.31 |
Enterprise Value | $952.76B | $11.32B |
Dividend Yield | 0.06% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $877.57, down 0.44% on the day, with technical indicators showing a neutral overall signal and bullish moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $25.11 versus $20.98 expected, driven by robust AI memory demand. Revenue surged to $37.38 billion in 2025, with net income margin at 55.91%. Analyst consensus is overwhelmingly bullish with an 81.43% buy rating and a $1,540 price target.
Outlook remains positive due to structural demand for high-bandwidth memory in AI, but risks include cyclical pricing pressures and competitive capacity expansions. The stock offers growth potential amid tight supply conditions, though volatility from valuation concerns and macroeconomic factors persists. Key support sits at $848 with resistance at $906.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
